Comparison of four immunohistochemical tests and FISH for measuring Her2 expression in gastric carcinomas

Pathology

Volumn 44, Issue 3, 2012, Pages 216-220

  Cho, Eun Yoon ^a   Srivastava, Amitabh ^c   Park, Kyeongmee ^b   Kim, Jiyun ^a   Lee, Min Hyeong ^d   Do, Ingu ^a   Lee, Jeeyun ^a   Kim, Kyoung Mee ^a   Sohn, Tae Sung ^a   Kang, Won Ki ^a   Kim, Sung ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Inje University   (South Korea)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Department of Obstetrics Gynecology   (United States)

Author keywords

Adenocarcinoma; Amplification; Carcinoma; Expression; Fluorescence in situ hybridization; Gastric; HER2; Immunohistochemistry; Stomach

Indexed keywords

EID: 84863650635     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283513e8b     Document Type: Article

References (42)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50. (Pubitemid 46655601)
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
3. Cutsem EV, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27 (Suppl): 18s.
4. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24. (Pubitemid 351377973)
5. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohisto-chemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199: 418-23. (Pubitemid 36411217)
6. van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer. Mod Pathol 2009; 22: 879-86.
7. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002; 20: 3095-105. (Pubitemid 34791099)
8. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18: 53-9.
9. Graziano C. HER-2 breast assay, linkedto Herceptin wins FDA's okay. CAP Today 1998:13-6.
10. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-32. (Pubitemid 46972801)
11. Press MF, Pike MC, Hung G, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 1994; 54: 5675-82. (Pubitemid 24346266)
12. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol 1999; 12: 827-34. (Pubitemid 29383887)
13. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58: 383-94.
14. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52: 797-805. (Pubitemid 351724903)
15. Ruschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457: 299-307.
16. Song Y, Huang J, Wang JW. Relationship between HER2/neu gene amplification and protein expression and prognosis in patients with advanced gastric carcinoma. Ai Zheng 2010; 29: 76-81.
17. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immuno-reactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034-8.
18. Roh JK, Paik S, Chung HC, et al. Overexpression of erbB-2 protein in gastric adenocarcinoma - a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen. Gan To Kagaku Ryoho 1992; 19: 1207-19.
19. Yonemura Y, Ninomiya I, Ohoyama S, et al. Correlation ofc-erbB-2 protein expression and lymph node status in early gastric cancer. Oncology 1992; 49: 363-7.
20. Uchino S, Tsuda H, Maruyama K, et al. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer 1993; 72: 3179-84. (Pubitemid 23356757)
21. Lee HR, Kim JH, Uhm HD, et al. Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. Oncology 1996; 53: 192-7. (Pubitemid 26131941)
22. Shun CT, Wu MS, Lin JT, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997; 44: 604-9.
23. Wu MS, Shun CT, Wang HP, et al. Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. Gastroenterology 1997; 112: 1457-65.
24. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 2000; 18: 2201-9. (Pubitemid 30350211)
25. Sanz-Ortega J, Steinberg SM, Moro E, et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 2000; 15: 455-62. (Pubitemid 30218839)
26. Wang YL, Sheu BS, Yang HB, Lin PW, Chang YC. Overexpression of c-erb-B2 proteins in tumor and nontumor parts of gastric adenocarcinoma - emphasis on its relation to H. pylori infection and clinicohistological characteristics. Hepatogastroenterology 2002; 49: 1172-6.
27. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98: 833-7. (Pubitemid 34286677)
28. Pinto-de-Sousa J, David L, Almeida R, et al. c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10: 247-56. (Pubitemid 35461524)
29. Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-9. (Pubitemid 44315804)
30. Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009; 33: 2112-8.
31. Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol 2009; 135: 1331-9.
32. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40: 769-77.
33. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value -conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65.
34. Nakajima M, Sawada H, Yamada Y, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894-902. (Pubitemid 29202761)
35. Lee KE, Lee HJ, Kim YH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol 2003; 33: 173-9. (Pubitemid 43102860)
36. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15: 65-71.
37. Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007; 38: 1386-93. (Pubitemid 47247482)
38. Im SA, Kim JW, Kim JS, et al. Clinicopathologic characteristics of patients with stage III/IV (M0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011; 20: 94-100.
39. Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010; 78: 26-33.
40. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. Cancer Res 1990; 50: 8002-9.
41. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 1993; 12: 2369-75. (Pubitemid 23194187)
42. Purdie CA, Jordan LB, McCullough JB, et al. HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 2010; 56: 702-7.